Use of serum BCMA levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone

Hematological Oncology ◽

10.1002/hon.2961 ◽

2022 ◽

Author(s):

Sean Bujarski ◽

Christine Sutanto ◽

Tanya M. Spektor ◽

Jennifer To ◽

Regina A. Swift ◽

...

Download Full-text